Close



Apr 12, 2024 02:30AM
Apr 3, 2024 09:00PM
Mar 25, 2024 09:00PM
Mar 25, 2024 06:31AM
Mar 25, 2024 06:30AM
Aug 19, 2022 10:39AM
Jul 4, 2022 09:00PM Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against First High-School, Upstart, Oscar Health, and Axsome and Encourages Investors to Contact the Firm
Jun 29, 2022 09:00PM
Jun 24, 2022 09:00PM
Jun 19, 2022 09:00PM
Jun 13, 2022 09:00PM
Jun 8, 2022 09:00PM
Jun 3, 2022 09:00PM
Jun 2, 2022 08:10AM Axsome Therapeutics (AXSM) PT Lowered to $29 at BofA Securities After KOL Call
May 29, 2022 09:00PM
May 23, 2022 09:00PM
May 18, 2022 09:00PM
Apr 25, 2022 08:29AM
Mar 1, 2022 09:21AM
Mar 1, 2022 07:00AM
Mar 1, 2022 07:00AM Axsome Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
Feb 8, 2022 09:19AM
Feb 7, 2022 05:45PM
Feb 7, 2022 05:14PM
Jan 14, 2022 07:20AM
Nov 8, 2021 07:00AM
Nov 8, 2021 07:00AM
Sep 14, 2021 09:28AM Pre-Open Stock Movers 09/14: (JCS) (LICX) (AXSM) Higher; (RDHL) (HLF) (WYNN) Lower (more...)
Sep 14, 2021 07:02AM
Sep 14, 2021 07:00AM
Sep 14, 2021 07:00AM
Sep 14, 2021 07:00AM
Aug 23, 2021 12:58PM
Aug 23, 2021 09:28AM
Aug 23, 2021 06:00AM Axsome Therapeutics Provides Update on the New Drug Application for AXS-05 for the Treatment of Major Depressive Disorder
Aug 23, 2021 06:00AM
Aug 9, 2021 01:33PM
Aug 9, 2021 07:05AM
Aug 9, 2021 07:05AM
Aug 9, 2021 07:05AM
Aug 9, 2021 07:00AM
Aug 9, 2021 07:00AM Axsome Therapeutics Announces AXS-05 Achieves Primary and Key Secondary Endpoints in the MERIT Phase 2 Trial in Treatment Resistant Depression
May 10, 2021 07:00AM
May 10, 2021 07:00AM
Apr 27, 2021 08:43AM
Apr 26, 2021 10:37AM
Apr 26, 2021 06:02AM
Apr 26, 2021 06:00AM
Apr 26, 2021 06:00AM Axsome Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for AXS-05 for Treatment of Major Depressive Disorder
Oct 17, 2018 07:02AM

12,332 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All